ethyl 2-(3,4-dichlorophenyl)ethanecarboximidate hydrochloride, 95.0%, 2g

4-Chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine, 95.0%, 10g

2-Bromo-4-(trifluoromethoxy)benzoic acid, 97%, 500mg

(2-Bromophenyl)urea, 95.0%, 5g

1-Benzyl-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one, 95%, 100mg

2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethanol, 95.0%, 100g

3-(2-Methoxyphenyl)thiophene-2-carboxylic acid, 95.0%, 250mg

3-BOC-3-AZABICYCLO[3.1.0]HEXANE-1-CARBOXYLIC ACID, 95.0%, 5g

Éster n-butílico del ácido acético, mínimo 99 %, para síntesis, 2,5 l, envase de vidrio

Ethyl 8-iodo-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate, 95+%, 250mg

3-METHYL-1H-PYRAZOLO[3,4-B]PYRIDIN-5-AMINE, 95%, 250mg

Solución ROTI®Cell Tripsina/EDTA (10x)

2-(3-(Trifluoromethyl)phenyl)nicotinic acid, 95+%, 250mg